未经证实:鼻咽癌(NPC)中的EB病毒(EBV)DNA定量是肿瘤负荷的指标,阶段和生存。尽管流行地区的EBV动态已经得到了广泛的研究和报道,来自非流行地区的数据是稀疏的。这项研究试图调查非流行地区NPC患者的EBV动态,并确定影响结果的因素。
UNASSIGNED:这是一项在印度南部三级护理中心进行的前瞻性观察性研究,招募了非转移性患者,活检证实NPC,适用于有或没有诱导化疗的根治性放化疗。两份血样,在开始任何抗癌治疗之前,第二次在治疗后6周,使用实时定量聚合酶链反应收集以定量EBVDNA。针对EBV病毒衣壳抗原(EBVVCAIgM)的抗体,还测量样品中的EBV早期抗原(EBVEAIgG)和EBV核抗原(EBVEBNAIgG)。然后分析了EBV动力学对结果的影响。
未经评估:本研究共纳入35名患者。33例具有可识别的EBVDNA(94.3%),并且组织学诊断为非角化未分化型鳞状细胞癌。EBVDNA和抗EBV抗体之间没有相关性。复合阶段与治疗前DNA滴度之间存在显着关联(p=0.030)。在最后一次随访中,没有临床上可证明疾病的患者的平均EBVDNA滴度较低,对于那些没有疾病的患者,EBVDNA滴度的降低显着(p=0.020)。
未经证实:血浆EBVDNA是WHO2型和3型肿瘤的准确可靠的NPC生物标志物,即使在非地方病区也是如此。
UNASSIGNED: Epstein-Barr virus (EBV) DNA quantification in nasopharyngeal cancer (NPC) is an indicator of the tumour burden, stage and survival. Although EBV dynamics in endemic regions has been extensively studied and reported, the data from non-endemic regions is sparse. This study attempts to investigate the EBV dynamics in NPC patients from a non-endemic region and also to identify the factors impacting the outcomes.
UNASSIGNED: This was a prospective observational study conducted at a tertiary care centre in South India and enrolled patients with non-metastatic, biopsy proven NPC, who were suitable for radical chemo-radiotherapy with or without induction chemotherapy. Two blood samples, one prior to initiation of any anticancer treatment, and second at 6 weeks post treatment, were collected to quantify EBV DNA using real-time quantitative polymerase chain reaction. Antibodies against EBV viral capsid antigen (EBV VCA IgM), EBV Early Antigen (EBV EA IgG) and EBV Nuclear Antigen (EBV EBNA IgG) were also measured in the sample. The impact of EBV dynamics on the outcomes was then analysed.
UNASSIGNED: The study included a total of 35 patients. Thirty-three had identifiable EBV DNA (94.3%) and a histological diagnosis of non-keratinising undifferentiated type of squamous cell carcinoma. There was no correlation between the EBV DNA and anti-EBV antibodies. There was a significant association between composite stage and pre-treatment DNA titre (p = 0.030). The mean EBV DNA titre was lower for patients with no clinically demonstrable disease at last follow-up and the reduction in EBV DNA titres was significant (p = 0.020) for those patients who remained disease free.
UNASSIGNED: Plasma EBV DNA is an accurate and reliable biomarker for NPC for WHO type 2 and 3 tumours even in non-endemic regions.